SCHEMBL29612754

SCHEMBL29612754

CCOC(=O)c1cnn(-c2cc(C)c(Br)c(C)c2)c1-c1ccccc1

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 9/20 0.76
HPGD P15428 5/20 0.54
SMN1; SMN2 Q16637 3/20 0.51
NPC1 O15118 3/20 0.50
MAPT P10636 2/20 0.50
TSHR P16473 2/20 0.50
CA1 P00915 1/20 0.49
CA2 P00918 1/20 0.49
RAB9A P51151 4/20 0.48
KDM4E B2RXH2 3/20 0.48
HSD17B10 Q99714 1/20 0.48
MEN1 O00255 2/20 0.47
GAA P10253 2/20 0.47
KMT2A Q03164 2/20 0.47
TDP1 Q9NUW8 2/20 0.47
CYP1A2 P05177 1/20 0.47
CYP3A4 P08684 1/20 0.47
CYP2C9 P11712 1/20 0.47
CYP2C19 P33261 1/20 0.47
HTT P42858 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4828987 0.87 ALDH1A1 (1.00) ALDH1A1HPGDSMN1; SMN2NPC1TSHR
SCHEMBL14406221 0.81 ALDH1A1 (0.84) ALDH1A1HPGDSMN1; SMN2NPC1MAPT
SCHEMBL14406230 0.80 ALDH1A1 (0.80) ALDH1A1HPGDSMN1; SMN2NPC1MAPT
SCHEMBL15750820 0.79 ALDH1A1 (0.84) ALDH1A1HPGDSMN1; SMN2NPC1TSHR
SCHEMBL14333125 0.78 ALDH1A1 (0.77) ALDH1A1HPGDSMN1; SMN2MAPTTSHR
SCHEMBL11890412 0.76 ALDH1A1 (0.71) ALDH1A1HPGDSMN1; SMN2NPC1MAPT
SCHEMBL5069717 0.75 ALDH1A1 (0.71) ALDH1A1HPGDSMN1; SMN2NPC1TSHR
SCHEMBL5062856 0.73 ALDH1A1 (0.67) ALDH1A1HPGDSMN1; SMN2NPC1MAPT
SCHEMBL14957025 0.73 ALDH1A1 (0.69) ALDH1A1HPGDSMN1; SMN2NPC1MAPT
SCHEMBL5481730 0.73 ALDH1A1 (0.65) ALDH1A1HPGDSMN1; SMN2NPC1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12168057-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2024-12-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12168057-B2 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 ALDH1A1 2776/4885HPGD 3843/4885SMN1; SMN2 2647/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.